ArticleOncology letters2017
E-cadherin: A potential biomarker of colorectal cancer prognosis.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Telmisartan Repurposing Targets Novel Biomarkers for Precision Colorectal Cancer Therapy.Pharmaceutics · 2026Article
- Antitumor effect of dipyridamole mediated by inhibiting the interaction between platelets and tumor cells.Discover oncology · 2026Review
- High glucose enhances NScientific reports · 2026Article
- Immunohistochemical Expression of Metastasis-Associated Gene 3 (MTA3) and Epithelial-Mesenchymal Transition (EMT) Markers in Colorectal Carcinoma: A Cross-sectional Study.Iranian journal of pathology · 2026Article
- Article
- Options and Considerations in the Management of Peritoneal Disease in Patients with Small Bowel Neuroendocrine Tumors.Current treatment options in oncology · 2025Review
- Patient-specific 3D-tissue slices from peritoneal metastases - AnPleura and peritoneum · 2025Article
- Integrating E-cadherin expression levels with TNM staging for enhanced prognostic prediction in colorectal cancer patients.BMC cancer · 2025Article
- The effect of novel nitrogen-based chalcone analogs on colorectal cancer cells: Insight into the molecular pathways.Heliyon · 2024Article
- The effects of thymidylate synthase 3'UTR genotype on methylation of tumor-specific genes promoter in 22 colorectal cancer patients from southern Iran.Molecular biology research communications · 2024Article
- Clinicopathological characteristics and outcomes of colorectal mucinous adenocarcinoma: a retrospective analysis from China.Frontiers in oncology · 2024Article
- Frequent Intraluminal Growth of Large Muscular Veins in Surgically Resected Colorectal Cancer Tissues: A 3-Dimensional Pathologic Reconstruction Study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023Article
- The platinum coordination complex inhibits cell invasion-migration and epithelial-to-mesenchymal transition by altering the TGF-β-SMAD pathway in colorectal cancer.Frontiers in pharmacology · 2023Article
- Recent progress in cancer cell membrane-based nanoparticles for biomedical applications.Beilstein journal of nanotechnology · 2023Review
- Epigenome-Wide Study Identifies Epigenetic Outliers in Normal Mucosa of Patients with Colorectal Cancer.Cancer prevention research (Philadelphia, Pa.) · 2022Article
- Article
- Altered expression of junctional proteins as a potential biomarker in oral precancerous and cancerous patients.Tissue barriers · 2022Article
- Review
- Investigation of the expression levels of CDH1, FHIT, PTEN, and TTPAL genes in colorectal tumors.Turkish journal of medical sciences · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a common and lethal disease. It is the third most common type of cancer in the world, behind lung and breast cancer, with almost 1.4 million new cases diagnosed in 2012. The risk of developing CRC is influenced by environmental and genetic factors. Adenocarcinomas comprise the vast majority (98%) of CRCs. A patient's likelihood of survival is associated with the tumor stage at the time of diagnosis. With regular screening, CRC can be identified early, when treatment is the most effective. However, CRC is typically asymptomatic until the advanced stages. The combination of the absence of symptoms and current screening methodology results in a significant number of patients being diagnosed in advanced stages. The purpose of the present review is to discuss and summarize the biomarkers linked to CRC progression, particularly the controversial E-cadherin, which is a calcium-dependent cell-cell adhesion molecule involved in the mesenchymal-epithelial transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.